Selected Grants
A Long-term Multicenter Prospective Observational Study Evaluating the Comparative Effectiveness and Safety of Sarepta Gene Transfer Therapy vs. Standard of Care in Participants with Duchenne Muscular
Clinical TrialPrincipal Investigator · Awarded by Sarepta Therapeutics, Inc. · 2025 - 2035ASK-POM9-CS1001
Clinical TrialPrincipal Investigator · Awarded by AskBio, Inc. · 2026 - 2035ITF-2357-62
Clinical TrialPrincipal Investigator · Awarded by ITF Therapeutics, LLC · 2026 - 2031MOVE+ Peds (Fixed rate)
ResearchPrincipal Investigator · Awarded by University of Kansas · 2025 - 2029MOVE+ Peds (Cost reimbursement)
ResearchPrincipal Investigator · Awarded by University of Kansas · 2025 - 2029Sarepta 9001-103 Gene Delivery Study
Clinical TrialPrincipal Investigator · Awarded by Sarepta Therapeutics, Inc. · 2026 - 2028Development of Novel Imaging Biomarkers for use in Pediatric Facioscapulohumeral muscular dystrophy
ResearchPrincipal Investigator · Awarded by American Academy of Neurology · 2023 - 2026Duchenne Outcomes Research Interchange Data Enrichment through EHR Extraction
ResearchPrincipal Investigator · Awarded by Parent Project Muscular Dystrophy · 2022 - 2026FSHD Clinical Trial Research Network Master Agreement
Clinical TrialPrincipal Investigator · Awarded by The University of Kansas Medical Center Research Institute, Inc · 2024 - 2025External Relationships
- Biogen
- Catalyst pharmaceuticals
- Dyne Therapeutics
- GLG Consultants
- Guidepoint Global, LLC
- ITF Therapeutics
- SOLVE FSHD
- Sarepta Therapeutics
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.